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Abstract
Background Hereditary breast cancer runs in families where
several members in different generations are affected. Most
of these breast cancers are caused by mutations in the high
penetrance genes BRCA1 and BRCA2 accounting for about
5% of all breast cancers. Other genes that include CHEK2,
PTEN, TP53, ATM, STK11/LKB1, CDH1, NBS1, RAD50,
BRIP1 and PALB2 have been described to be high ormoderate
penetrance breast cancer susceptibility genes, all contributing
to the hereditary breast cancer spectrum. However, in still
a part of familial hereditary breast cancers no relationship to
any of these breast cancer susceptibility genes can be found.
Research on new susceptibility genes is therefore ongoing.
Design In this review we will describe the function of the
today known high or moderate penetrance breast cancer
susceptibility genes and the consequences of their mutated
status. Furthermore, we will focus on the histology, the
immunophenotype and genotype of breast cancers caused
by mutations in BRCA1 and BRCA2 genes and the other
high or moderate penetrance breast cancer susceptibility
genes. Finally, an overview of the clinical implications of
hereditary breast cancer patients will be provided.
Conclusion This information leads to a better understand-
ing of the morphological, immunohistochemical and mo-
lecular characteristics of different types of hereditary breast
cancers. Further, these characteristics offer clues for
diagnosis and new therapeutic approaches.
Keywords Hereditary breast cancer . BRCA1 . BRCA2 .
Pathology . Genetics
1 Introduction
In 1866, Paul Broca was the first to describe a family
with a high prevalence of carcinoma of the breast. His
wife suffered from early onset of breast cancer and when
he made a pedigree of her family, four generations with
breast cancer could be identified [24]. The “Broca” report
is the first of many that pointed out that breast cancer can
be inherited, passing through from one generation to the
other. Family history of breast cancer is now an estab-
lished risk factor for the development of the disease. In
fact, among those variables that have been shown to bear a
causal relationship with breast cancer, the highest in-
creased risk, after age, is a positive family history of breast
cancer [31]. With the knowledge of today, only in about
5% of all the breast cancer cases, the disease will occur as
part of a hereditary cancer susceptibility syndrome, caused
by mutations in high penetrance susceptibility genes. A
substantial proportion of hereditary breast cancers, about
16% [2, 138], can be attributed to germline mutations in
either of the BRCA (breast cancer 1 and 2) early onset genes.
Since the identification of the BRCA1 and BRCA2 genes in
1994, several studies have been undertaken to find other high
penetrance breast cancer susceptibility genes than BRCA1
and BRCA2, with less spectacular results so far [124].
Nevertheless, various other genes conferring an in-
creased risk of breast cancer involved in hereditary cancer
syndromes have been identified, including CHEK2, PTEN,
TP53, ATM, STK11/LKB1, CDH1, NBS1, RAD50, BRIP1
and PALB2. Some of these genes are involved in multiple
cancer syndromes like Li-Fraumeni (TP53), Peutz-Jeghers
(STK11/LKB1) and Cowden syndrome (PTEN) [49, 69, 94,
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125, 161]. In Table 1, an overview of the hereditary cancer
susceptibility syndrome genes is shown, including their
chromosomal location, which syndrome is involved and the
clinical features of these syndromes.
In this paper, we will mainly focus on the hereditary
breast cancer syndromes caused by germline mutations in
the BRCA1 and BRCA2 genes since these have been well
studied for their pathological features. Thereafter, we will
briefly discuss the rarer hereditary cancer susceptibility
syndrome genes mentioned earlier where yet little is known
on tumor pathology [8, 140, 174].
1.1 The BRCA1 and BRCA2 genes
1.1.1 Discovery
The BRCA1 and BRCA2 genes were discovered in the
nineties, starting in 1990 where BRCA1 was for the first
time linked to breast cancer using a large group of early
onset breast cancer families and linkage analysis. The
BRCA1 gene was mapped to chromosome 17q21 [57]. In
1994, the BRCA1 gene was cloned and truncating mutations
were identified in the coding sequence of the BRCA1 gene
in families with multiple cases of breast cancer [118].
Search for more genes that might be involved in these
hereditary susceptibility breast cancer families led in 1995
to the discovery of the BRCA2 gene. The BRCA2 gene is
located on chromosome 13q12.3, and was discovered also
by linking analysis and positional cloning using familial
breast cancer pedigrees in successive generations [201,
202]. At the same time, families with high frequencies of
male breast cancer were found to carry the BRCA2 mutation
[167].
Carriers of the BRCA1 and BRCA2 mutations do not
only develop breast cancer and ovarian cancer but also bear
an increased risk for developing Fallopian tube, colon,
melanoma, prostate and pancreatic cancer [56, 83, 93, 123,
128, 131, 206].
Table 1 Summary of the syndromes associated with hereditary breast cancer, adapted from Tan et al. [170]
Gene involved Cytoband Breast cancer risk Syndrome Clinical features
BRCA1 17q21 High Hereditary breast cancer and
ovarian syndrome
Breast cancer, ovarian cancer
BRCA2 13q12.3 High Hereditary breast cancer and
ovarian syndrome
Breast cancer, ovarian cancer, prostate cancer,
pancreatic cancer, melanoma
TP53 17p13.1 High Li-Fraumeni syndrome Breast cancer Sarcomas Brain tumors
ATM 11q22.3 Intermediate Louis-Bar syndrome Lymphoma, cerebellar ataxia, immune deficiency,
glioma, medulloblastoma, breast cancer
CDH1 16q22.1 Intermediate Familial diffuse gastric cancer
syndrome
Gastric cancer, lobular breast cancer
PTEN 10q23.31 Intermediate Cowden syndrome Increased risk of neoplasms: breast cancer, thyroid
cancer, endometrial carcinomas, hamartomatous
polyps of the gastrointestinal tract
Bannayan-Riley-Rivalcaba syndrome Breast cancer, meningioma
STK1 19p13.3 Intermediate Peutz-Jeghers syndrome Melanocytic macules of the lips and others multiple
gastrointestinal hamartomatous polyps increased
risk of neoplasms; breast, testis, pancreas and cervix
NBS1 8q21 Intermediate Nijmegen breakage syndrome Microcephaly,growth retardation, immunodeficiency
and a marked susceptibility to cancer
Moderate risk of breast cancer
BRIP/FANCJ 17q22 Intermediate Fanconi anemia Developmental anomalies affecting the skeleton
(absent or abnormal thumbs and radii), kidneys,
heart or any other major organ system
PALB2/FANCN 16p12 Intermediate Aplastic anaemia, acute myeloid leukaemia and
squamous cell carcinoma, breast cancerFANCA 16q24.3 Low
FANCE 6p22-p21 Low
MSH2 2p22-p21 Low Lynch cancer family syndrome Endometrial cancer, colorectal cancer, breast cancer,
ovarian cancer, genitourinary cancer, sarcomas,
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1.1.2 Structure
Both BRCA genes bear rather complex genomic structures.
BRCA1 is composed of 24 exons and BRCA2 of 27 exons.
They both encode very large proteins: BRCA1 consists of
1,863 amino acids and BRCA2 of 3,418 amino acids. In
both genes, exon 1 is non-coding and exon 11 is unusually
large [163, 201, 202] (Fig. 1). BRCA1 has a highly
conserved zinc-binding RING finger domain which is
located close to the amino-terminus. RING finger domain
proteins are recognized as E3 ligase enzymes that partici-
pate in ubiquitination [110]. Mutations in the RING finger
domain inactivate BRCA E3 ligase and have an effect on
the other tumor suppressor activities of BRCA1 [152].
Towards the carboxyl terminus of BRCA1 two tandem
copies of the same motif are found, designated the BRCT
domains. These BRCT domains are regions reported to
activate transcription when fused to a DNA binding domain
[27]. BRCA2 contains a number of recognizable motifs, the
eight copies of a 20–30 amino acid repeat, termed BRC
repeats and the ssDNA binding region. Their function is to
bind to RAD51 to regulate DNA repair (Fig. 1) [95, 198].
1.1.3 Function
Both BRCA genes are involved in DNA repair. They form
complexes that will activate the repair of double strand
breaks (DSBs) and initiate homologous recombination
(HR). RAD51 is the key component of this mechanism.
Co-localization of BRCA1 and BRCA2 with RAD51 at the
site of recombination and DNA damaged induced foci
strongly suggest that they are involved in the detection and
the repair of DSBs. The roles played by BRCA1 and
BRCA2 in this process appear to differ. Small ubiquitin-like
modifier ligases are essential for localization of BRCA1 at
the sites of DNA damage and sumoylated BRCA1 itself,
together with BARD1 acts as E3 ligase and further
ubiquitinates local proteins [47, 121]. BRCA1 will associ-
ate with RAD51 upon DNA damage and subsequently gets
phosphorylated, but the nature of interaction with RAD51
is yet unknown [156]. BRCA2 has a more direct role
through its strict interaction with RAD51 via the BRC
repeats [200]. In addition, RAD51 also interacts with the C-
terminal region of BRCA2, TR2 [119, 160]. This part of
BRCA2 is thought to serve a regulatory role in recombina-
tional repair. Phosphorylation of this part of BRCA2 can
provide a dual function, resulting in inhibition or activation
during HR [36, 40]. BRCA2 also has a role in the HR in
meiosis via an interaction with RAD51 and DMC1. Given
the fact that they have distinct non-overlapping binding
sites, it has been suggested that there might well be a
BRCA2-RAD51-DMC1 complex. However, more data has
to be obtained to confirm this. It does suggest that BRCA2
not only plays a role in carcinogenesis but in addition
contributes to fertility problems in affected carriers [176].
Cells that are defective for BRCA1 and BRCA2 are
hypersensitive for crosslinking agents that will produce
double strand breaks like mitomycin c and cisplatin [122,
135, 172]. Also, ionizing radiation will produce these same
breaks and both will be resolved by error-prone repair, such
as non homologous end joining [204, 205]. The levels of
expression of BRCA1, BRCA2 and RAD51 increase in
cells when they enter the S phase, indicating that they
























Fig. 1 Schematic representation
of BRCA1 and BRCA2 func-
tional domains and selected bind-
ing partners, partially adapted
from Narod et al. [124]. NLS =
Nuclear Localization signal.
Some of the proteins interacting
with BRCA1 or BRCA2 are
marked below the site of
interaction
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BRCA1 and BRCA2 function in a common pathway that is
responsible for the integrity of the genome and the
maintenance of chromosomal stability [157]. BRCA1 is
part of the BRCA1 associated genome surveillance com-
plex (BASC) This complex includes MSH2, MSH6,
MLH1, ATM, BLM , the RAD50-MRE11-NBS1 complex
and the DNA replication factor C. All the members of this
complex have roles in recognition of abnormal or damaged
DNA, suggesting that the BASC may serve as a sensor for
DNA damage and as a regulator of the post-replication
repair process. BRCA1 functions also as a checkpoint
control, playing an essential role in cell survival by
preventing the propagation of DNA damage through cell
cycle progression before DNA repair has taken place [197].
Taken together, BRCA1 is an integral part of the DNA
damage signalling cascade; downstream of ATM and ATR
kinases and both downstream and upstream of the check-
point protein kinases CHEK1 and CHEK2 suggesting that
there is a positive feedback loop to increase the magnitude
of DNA damage response. In addition, BRCA1 regulates
the expression of additional G2M cell cycle checkpoint
proteins thereby preventing unscheduled transition into
mitosis at multiple levels of regulation. Ubiquitination is
the process by which proteins are tagged for degradation by
the proteasome. BRCA1 functions with BARD1 in this
ubiquitination process [144]. It has been suggested that
BRCA1 plays a role in both transcription coupled repair
[103] and global genome repair [59]. So, in conclusion,
both BRCA genes are involved in DNA repair and both
function in a common pathway that is responsible for the
integrity of the genome and the maintenance of chromo-
somal stability.
1.1.4 Mutations
The Breast Cancer Information Core (BIC) database has
recorded 1,639 and 1,853 distinct mutations, polymor-
phisms and variants in the BRCA1 and BRCA2 genes,
respectively (data 2010). Mutations appear to be reasonably
evenly distributed across the coding sequences, with no
obvious “mutation hot spots”. Most mutations found in the
breast and ovarian cancer families are predicted to truncate
the protein product, which will lead to shortened and non-
functional BRCA1 and BRCA2 proteins. The most com-
mon types of mutations are small frameshift insertions or
deletions, non-sense mutation or mutations affecting splice
sites, resulting in deletion of complete or partial exons or
insertion of intronic sequences. These mutations will cover
approximately 70% of the BRCA1 mutations and 90% of
the BRCA2 mutations in linked families, as estimated by the
Breast Cancer Linkage Consortium (BCLC) [174]. Large-
scale rearrangements including insertions, deletions or
duplications of more than 500 kb of DNA have also been
identified. There have been reports of at least 19 distinct large
genomic rearrangements in BRCA1 and two genomic
rearrangements in BRCA2, identified using multiplex ligation
dependent probe amplification (MLPA). The majority of the
rearrangements are deletions of one or more exons [73, 120].
These mutations can be all classified with reasonable
confidence but classification of rare missense changes is still
a challenge. According to the BIC database, approximately
half of the unique BRCA1 and BRCA2 variants detected
(excluding common polymorphisms) are missense variants of
unknown pathogenic potential, termed “unclassified variants”.
Note of concern here is that the BIC database did not take into
account the frequency in which these variants were found in
the population undergoing testing. Furthermore, the clinical
relevance of only a few unclassified variants has been
established. For the others, the subtle alteration might not
alter the function of the protein and there might also be
insufficient information about the family history to classify
these unclassified variants as cancer predisposing changes.
However, these alterations can provide indications to do
further functional and family studies [30, 104]. It has been
stated that a new approach is needed to improve the
association between these unclassified variants and breast
cancer risk, and that using histopathology data of tumors
from carries of an unclassified variant could be helpful [165].
Loss of heterozygosity (LOH) of the wildtype allele has
been robustly demonstrated for BRCA linked breast cancer.
Although some of the studies mentioning a role of LOH in
approximately 80% of the cases included in the studies, for
the rest of the cases LOH affecting the BRCA gene could
not be detected [32, 33, 54, 127]. This might be caused by
the practical and conceptual problems associated with LOH
studies [178]. Furthermore, LOH of the wild type allele is
not required for BRCA linked breast tumorigenesis and
when it occurs it is probably a late event [92]. Another
consideration is whether a second somatic mutation or
methylation dependent silencing affecting the wild type
allele accounts for these findings. However, no evidence
of a second somatic mutation in BRCA linked breast
cancer has been found so far. BRCA promoter hyper-
methylation as a gene silencing mechanism has been
reported in 11%–30% and 42%–51% of sporadic breast
cancer and non-BRCA1/BRCA2 related hereditary breast
cancers, respectively [19, 42, 76, 171]. BRCA1 and BRCA2
related breast tumours only rarely showed BRCA promoter
hypermethylation [37, 41, 169, 171]
1.1.5 Population specific occurrence
The majority of all the mutation described above are found
throughout the population. However, certain mutations in
BRCA1 and BRCA2 have been observed to be common in
specific populations. Such founder mutations in BRCA1
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and BRCA2 have been described in French Canadian [162],
Swedes [86], Icelandic women [175], Norwegians [7],
Finns [80], Dutch women [136, 139], Russians [50],
Japanese women [82] and African Americans [48]. Three
founder mutations are very commonly found in the
Ashkenazi Jewish population, the 185delAG [129, 168]
and 5382insC in BRCA1 and 6147delT in BRCA2 [9, 126].
The 185delAG is prevalent in 1% of all Ashkenazi Jews but
has also been reported in other Jewish groups [16]. The
5382insC mutation found in 0.1% of the Ashkenazi Jews is
described to occur more widespread, being common in
Poland, Russia, and other parts of Eastern Europe and
occurring in most European populations. In Ashkenazi
Jewish women with breast cancer, the 185delAG mutation
in BRCA1 is found in 20% [130]. The 6147delT mutation
in BRCA2 is found to be present in 8% of the Ashkenazi
Jews with breast cancer [126, 179]. In Iceland, a single
BRCA2 mutation 999del5 has been identified and is present
in the majority of familial breast cancer cases in this
population [55, 175].
1.2 Pathology of BRCA1 related breast cancer
1.2.1 Histology
The histology of BRCA1 associated breast cancers differs
from the histopathological features of sporadic breast
cancers in various aspects. The majority of the BRCA1
associated tumors are invasive ductal adenocarcinomas
(74%). However, compared to sporadic breast cancer, a
significantly higher frequency of the BRCA1 associated
tumors are classified as medullary like carcinomas, 2%
versus 13% respectively [1, 99]. The remaining histological
types of breast cancer occur about equally in BRCA1
mutation associated tumors and in sporadic breast cancer
[1]. With regard to other histopathological characteristics it
is observed that BRCA1 tumors are more frequently poorly
differentiated (grade 3), have a high mitotic count and show
an high frequency of necrotic areas [186]. Tubule formation
is decreased, but a higher degree of pleimorphism is
observed, all aspects pointing at a more aggressive
phenotype [10, 75, 99, 112]. In addition, tumors are often
well demarcated and show a remarkable degree of
lymphoplasmocytic infiltration, and a high frequency of
lymphovascular invasion [66].
When considering the age of onset of these BRCA1
mutation carriers, less than 50 years of age compared to age
above 50 years, significant differences in grade (higher) and
in percentage of medullary type (more cases), of breast
cancer are seen in the younger population [38]. With regard
to pre-invasive breast lesions, it has initially been reported
that ductal carcinoma in situ (DCIS) and lobular carcinoma
in situ (LCIS) are seen less frequently in BRCA1 mutation
carriers, being 41% and 2% respectively versus 56% and 6%
in non-carriers. These concerned however pre-invasive
lesions in cases where invasive breast cancer was seen [1,
13]. Studies investigating the occurrence of premalignant
lesions in prophylactic mastectomies of BRCA1 mutation
carriers usually showed more frequent occurrence of
premalignant lesions. These premalignant lesions concern
DCIS [79, 84, 90], LCIS [79], atypical ductal (ADH) [71,
79, 84, 90] and atypical lobular hyperplasia (ALH) [71, 79,
84, 90], usual ductal hyperplasia [71], columnar cell lesions
[90] and fibroadenoma [71, 97]. Interestingly, the remarkable
lymphocytoplasmic infiltrate described in invasive BRCA1
related cancers has also been described in DCIS lesions and
even the normal breast shows T-cell lobulitis [72].
1.2.2 Immunophenotype
The immunophenotype of the BRCA1 mutation related
breast cancers (Table 2) is first of all characterized by a low
expression of the estrogen receptor alpha (ERα). In 1997
the first reports about the low expression of ERα in BRCA1
tumors compared to sporadic tumors were described.
Subsequent reports confirmed this observation and in
addition described a significant relationship between low
ERα on the one hand and high grade [11, 38, 44, 87, 88,
Table 2 Expression of different immunohistochemical markers in
BRCA1 and BRCA2 germline mutation related breast cancers relative
to sporadic breast cancers (? indicates not known)
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101, 111, 134] and an earlier age of onset [38, 44, 192] on
the other. In contrast, overexpression of estrogen receptor
beta (ERβ) is seen in breast cancers of BRCA1 mutation
carriers [109]. Similar low expression of the progesterone
receptor (PR) has been reported [11, 38, 101, 111, 134].
Overall, the expression of the human epidermal growth
receptor 2 (HER-2/neu) is low in BRCA1 related breast
cancers when compared with controls [11, 75, 101].
Furthermore, HER-2/neu amplifications among BRCA1
tumors have only rarely been reported. One explanation
could be that in the background of a BRCA1 germline
mutation, HER-2/neu is lost during loss of heterozygosity
(LOH) at the BRCA1 locus since HER-2/neu is localized
close to BRCA1 on chromosome 17 [3, 53, 134].
In contrast to HER-2/neu, overexpression of the
epidermal growth factor receptor (EGFR) has been
strongly associated with BRCA1 associated breast cancers
[45, 100, 187, 188, 191].
BRCA1 related breast cancers often lack cyclin D1
(CCND1) expression. Also the expression of p27Kip1 is
very low in BRCA1 related breast cancers and this is seen
together with high levels of cyclin E [44]. Mutations in the
TP53 gene are seen in 30%–77% of BRCA1 tumors
whereas they are only present in about 20% of sporadic
controls. As a consequence, accumulation of p53 is often
seen in BRCA1 related breast cancer. Furthermore, the
distribution of the TP53 mutations might be influenced by
the BRCA1 and BRCA2 genes [11, 34, 52, 74, 141].
Evaluating the expression of several basal markers in
BRCA1 related breast cancers it was observed that most of
these tumors are positive for cytokeratins CK5/CK6 and
CK14 [45, 100], caveolin 1[143], vimentin, laminin [151]
and p-cadherin [12].
Expression of the apoptosis related proteins BAX and
BCL2 in BRCA1 related breast cancers is lower compared
to sporadic breast cancers is reported [46, 133, 134]. In
contrast, high levels of active caspase 3 were observed in
BRCA1 tumors [133]. Hypoxia inducible factor-1α (HIF-
1α) is the key regulator of the hypoxia response. HIF-1α is
overexpressed during sporadic breast carcinogenesis [22]
and correlated with poor prognosis [21, 195]. It appears to
be involved in BRCA1 related breast cancers, where HIF-
1α is overexpressed in most of these tumors [186].
Expression of the stem cell marker ALDH1 appeared to
be higher in BRCA1 related breast cancers compared to
sporadic cancers [64] , indicating that these cancers bear an
increased cancer stem cell compartment. Intrestingly, there
was no difference between normal breast tissue of BRCA1
mutation carriers and controls [65]
Altogether, this immunophenotype indicates that BRCA1
related invasive breast cancer largely shows the immunophe-
notype of progenitor cells of the breast, indicating that they
initially may (in contrast to BRCA2 related cancers, see below)
derive from these cells. While the immunophenotype of
invasive BRCA1 related cancers has been well studied little is
yet known on the immunophenotype of pre-invasive lesions
from the BRCA1 carcinogenetic spectrum. We recently showed
that the immunophenotype of DCIS in BRCA1 carriers is
similar to that of their accompanying invasive cancers [190].
1.2.3 Genetic profile
Gene expression profile analysis has provided a tool to
distinguish distinct subtypes of breast cancers [137, 164].
Based on these data BRCA1 associated breast cancers are
classified as basal. The gene expression profile of BRCA1
associated tumors involves genes that were found to have
functions in proliferation, angiogenesis, cell motility, cell
adhesion, transcription and DNA repair. As mentioned
above, BRCA1 related breast tumors express basal markers
like CK 5/6, CK14, EGFR, P-cadherin and caveolin 1,
vimentin and laminin, thereby confirming the basal subtype
as established by immunohistochemistry [45, 100, 151].
These data further underline that carcinogenesis in BRCA1
germline mutation carriers very often occurs within the
“basal” progression route.
Promotor hypermethylation of tumor suppressor genes
has been shown to be somewhat less abundant in BRCA1
germline mutation related breast cancers [169], although it
is still clearly higher than in normal tissue.
As to copy number changes, a different pattern of
chromosomal copy-number gains and losses compared to
sporadic controls has been found. Copy number changes
frequently occurring in BRCA1 related breast cancers are
gains of 3q, 7p, 8q 10p, 12p, 16p and 17q and loss of 2q, 3p,
4p, 4q, 5q, 12q, 16p and 18q. This only partly overlaps with
copy number changes found in sporadic and BRCA2 germline
mutation related breast cancers, see Table 3 [177, 185, 199].
1.2.4 Prognosis
In BRCA1 associated tumors, a lower rate of bone metastases
and a higher frequency of lung and brain metastases have
been described [96]. Investigating overall survival in BRCA1
associated breast cancer versus age matched sporadic breast
cancer patients have yielded contradictive results with some
studies describing a worse survival and others a similar
survival rate [23, 58, 107, 147, 150, 194].
1.3 Pathology of BRCA2 related breast cancer
1.3.1 Histology
Similar to BRCA1 related breast cancers, the most common
histological type in BRCA2 tumors is invasive ductal
carcinoma (76%) [1]. Reports of a higher incidence of
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tumors belonging to invasive (pleiomorphic) lobular,
tubular and cribiform carcinomas in BRCA2 related breast
cancers compared to sporadic breast cancer have been
published [4, 10, 14, 99, 112, 113]. BRCA2 tumors are
more frequently moderately or poorly differentiated
carcinomas (grade 2 and 3) [4, 99, 111, 134] due to less
tubule formation [1] more nuclear pleiomorphism and
higher mitotic rates compared to controls [4, 14]. BRCA2
related breast cancers have, as BRCA1 related cancers, a
higher proportion of continuous pushing margins in
comparison to sporadic breast cancers [14, 99]. With
regard to pre-invasive breast lesions it has been described
that DCIS and LCIS in BRCA2 mutation carriers occur in
the same frequency, 52% and 3% respectively compared
to 56% and 6% in control individuals [1, 13, 78]. The
occurrence of premalignant lesions in prophylactic mastecto-
mies of BRCA2 mutation carriers show different results,
similar to what has been observed in BRCA1 mutation
carriers, ranging from no differences to the more frequent
occurrence of premalignant lesions in prophylactic mastec-
tomies of BRCA2 mutation carriers like DCIS [79, 90], LCIS
[79, 84], ADH [71, 79, 84, 90], ALH [71, 79, 84, 90] and
columnar cell lesions [90]. Interestingly, the remarkable
lymphocytoplasmic infiltrate described in invasive BRCA2,
and in BRCA1 as mentioned before, related cancers has also
been described in DCIS lesions, and even the normal breast
shows T-cell lobulitis [72].
1.3.2 Immunophenotype
The immunophenotype of BRCA2 related breast cancers is
similar to the immunophenotype of sporadic breast cancers
(Table 2). As a consequence, most BRCA2 tumors show a
different immunophenotype compared to BRCA1 related
breast tumors as discussed above. BRCA2 cancers show
more frequently expression of ERα and PR [4, 10, 14, 38,
45]. Furthermore, these ER positive BRCA2 related breast
cancers decrease in frequency with increasing age [44]. In
BRCA2 related breast cancer different studies report no or
low expression of HER-2/neu compared to sporadic breast
cancer and only in rare cases a HER-2/neu amplification
was found [14, 101, 132, 134]. Furthermore, a more recent
study described that BRCA2 related breast cancers are
characterized by a higher expression of fibroblast growth
factor 1 (FGF1) and fibroblast growth factor receptor 2
(FGFR2) compared to BRCA1 related breast cancers. This
could help to distinguish BRCA2 related breast cancers
from other breast cancers [15]. The BRCA2 related breast
cancers usually express only “luminal” cytokeratins like
CK8 and CK18 and not CK5/6 and CK14 [133]. In BRCA2
related breast cancers no expression of caveolin1 has been
described in contrast to the expression of caveolin in BRCA1
related tumors [143]. No differences or even lower levels of
the incidence of p53 have been reported for BRCA2 related
breast cancers in comparison with BRCA1 related breast
cancers [133]. Higher expression of cyclin D1, BAX and
BCL2 in BRCA2 related breast cancers compared to BRCA1
and non-BRCA carriers have been described [133, 134].
However, anecdotic data suggest that EGFR expression is
high in BRCA2 related cancers [188]. While BRCA1 related
cancers have been described to be frequently positive for
P-cadherin, vimentin and HIF-1α, no such data are yet
available for BRCA2 related cancers. No data on ALDH1
expression in BRCA2 related cancers are available.
Locus Frequency p-value







1cen-p13 89 68 87 0.054
3pter-p22 33 16 0 0.006
3q13-q27 67 56 13 0.000 0.073
8p12-cent 11 16 47 0.012
9p 33 16 3 0.078
9q22-q34 0 32 3 0.013
10pter-p12 50 20 7 0.000
10p12-q21 36 4 3 0.089
13q3 25 8 0 0.059
16p 17 24 57 0.019
18p 28 16 3 0.025
Losses
5cent-q23 72 40 27 0.025
14q1-q2 39 8 10 0.048
Table 3 Chromosomal loci
showing significant differences
in frequency of gain or loss by
array comparative genomic
hybridization between BRCA1
and BRCA2 related and
sporadic breast cancers [185]
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While the immunophenotype of invasive BRCA2
related cancers has been well studied, little is yet known
on the immunophenotype of pre-invasive lesions from the
BRCA2 carcinogenetic spectrum. We recently showed that
the immunophenotype of DCIS in BRCA2 carriers is
similar to that of their accompanying invasive cancers
[190].
In conclusion, most of the BRCA2 related breast cancers
are of the so called luminal type with overexpression of ER,
PR, CK8 and CK18. This is clearly different from the
observations in BRCA1 related breast cancers [101, 134],
pointing to a different origin from the luminal cells of the
breast rather than the progenitor cells as in BRCA1 related
breast cancer.
1.3.3 Genetic profile
In a recent study using gene expression analysis to
distinguish BRCA2 associated tumors, discriminating genes
were those related to transcription, signal transduction, cell
proliferation, cell adhesion and extracellular matrix remod-
elling. In this study, a relative high expression of FGF1 and
FGFR2 was observed and this was confirmed by immuno-
histochemistry as stated above [15, 61, 184, 199]. When
using the gene expression profile mentioned before, most of
the BRCA2 related breast cancers were classified as luminal
[137, 164]. Looking more specifically at the molecular
genetics, BRCA2 related breast cancers show patterns of
chromosomal copy-number gains and losses that are not found
in sporadic controls. Copy number changes more frequently
occurring in BRCA2 related breast cancers are gains of 8q,
17q22-q24 and 20q13 and loss of 8p, 6q, 11q and 13q [177,
185], see Table 3.
1.3.4 Prognosis
In women with BRCA2 associated breast cancer, bone and
soft tissue metastases are observed more frequently likely
associated with their more frequent ER positivity [96]. As
is the case in BRCA1 patients, for BRCA2 patients
conflicting data with regard to outcome have been
presented [23, 58, 107, 147, 150, 194].
1.4 Other hereditary breast cancer genes
1.4.1 TP53
TP53 (tumor protein p53) is a tumor suppressor gene located
on chromosome 17p13.1 encoding a nuclear phosphoprotein
(p53). TP53 acts as a transcription factor involved in the
control of cell cycle progression, repair of DNA damage,
genomic stability, and apoptosis [196]. TP53 is constitution-
ally mutated in the Li-Fraumeni syndrome, an autosomal
dominant predisposition to breast cancer and other forms of
cancer (see Table 1). Most mutations are point mutations
leading to proteins defective for sequence-specific DNA
binding and activation of p53 responsive genes [49, 94, 161].
The TP53 gene is more commonly altered in BRCA1 (56%–
100%) and BRCA2 (29%) related breast cancer in compar-
ison with non-BRCA related breast [29, 74]. In BRCA1 or
BRCA2 deficient cells changes were seen at TP53 codons
that are not the mutation hotspots. Structural modelling
showed that most of these p53 non-hot spot aminoacids are
distributed in a region of the protein on the opposite side of
the p53 DNA-binding surface in these BRCA1 or BRCA2
deficient cells [52]. Breast cancers with these TP53 non-hot
spot mutations were associated with a significantly better
prognosis when compared with TP53 mutations in conserved
or structural domains [6]. Preliminary data suggest that
BRCA1 or BRCA2 mutations influence the distribution of the
TP53 mutations and the way of carcinogenesis, but
additional studies must be performed to support this [52].
1.4.2 CHEK2
The CHEK2 (checkpoint kinase 2) gene is located on
chromosome 22q12.1 and encodes a cell cycle checkpoint
kinase which is a key mediator in DNA damage response
[115, 203]. Mutations in CHEK2 were originally thought to
result in the Li-Fraumeni syndrome or in a Li-Fraumeni-
like syndrome (mentioned above and described in Table 1),
since the first CHEK2 mutations were found in these Li-
Fraumeni families [18]. More recent studies question this
association, following the identification of the 1000delC
and 1157T CHEK2 germline variants among breast cancer
patients that otherwise show no signs of Li-Fraumeni like
features [5, 183]. The CHEK2 gene has been proposed to
be a low penetrance breast cancer susceptibility gene. The
1000delC variant results in an approximately two fold risk
of breast cancer in women and a tenfold risk in men. In
these cases, there is no mention of co-existence of BRCA1
and BRCA2 mutations [117, 182]. So far, beside the
1000delC and 1157T mutations, no additional CHEK2
mutations have been found [155].
1.4.3 ATM
The ATM (ataxia teleangiectasia mutated) gene is located
on chromosome 11q22.3 and encodes a checkpoint kinase
that plays a role in DNA repair. Biallelic mutations in this
gene are linked to the rare human autosomal recessive
disorder called ataxia teleangiectasia (AT) [153], causing a
variety of somatic disorders as described in Table 1. A
heterozygous mutation of ATM does not lead to the AT
phenotype but carriers have a two to five fold risk of breast
cancer [148, 173] (Table 1).
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1.4.4 CDH1
CDH1 (Cadherin 1, E-cadherin) is a gene located on
chromosome 16q22.1 encoding E-cadherin, a calcium
dependent cell adhesion glycoprotein, which is important
for cell-to-cell adhesion [17]. Familial diffuse gastric
cancer, an autosomal dominant cancer syndrome is caused
by mutations in the CDH1 gene and affected women are
predisposed to lobular breast cancer. Patient with a familial
diffuse gastric cancer have a risk of about 50% of getting
breast cancer [91, 154] (Table 1).
1.4.5 PTEN
PTEN (phosphatase and tensin homolog), is a tumor
suppressor gene located on chromosome 10q23.3. PTEN
encodes for the protein phosphatidylinositol phosphate
phosphatase and has multiple and as yet incompletely
understood roles in cellular regulation[106, 166]. Germline
mutations in PTEN can lead to a rare autosomal dominant
inherited cancer syndrome, Cowden disease, characterized
by a high risk of breast-, thyroid- and endometrial
carcinomas and hamartomas [125]. Mutations in PTEN
also cause the related syndrome, Bannayan-Riley-Rivalcaba
syndrome [114], see for more details Table 1.
1.4.6 STK11
STK11 (LKB1) (Serine/theronine kinase 11) is a gene
located on chromosome 19p13.3 that encodes a serine/
threonine kinase and functions mainly through inhibition of
the mTOR pathway. STK11 is mutated in the autosomal
dominant condition Peutz-Jeghers syndrome, characterized
by perioral pigmentation and hamartomatous polyposis
[69]. Patients with this syndrome have a 30%–50% risk of
developing breast cancer [51, 60, 108] (Table 1).
1.4.7 NBS1
NBS1 is a gene located on chromosome 8q21 and involved
in the Nijmegen breakage syndrome, a chromosome
instability syndrome. Proteins of the gene NSB together
with proteins of the genes RAD50 and MRE11, form the so
called MRN complex. The MRN complex is involved in
the recognition and repair of DNA double strand breaks
[102]. The estimated prevalence of the most common
mutation is very low and the breast cancer risk conferred
by a NBS1 mutation is estimated to be low [20].
1.4.8 FANCONI
A rare recessive repair defect disorder called Fanconi anaemia
(FA) is linked to a number of genes, in total 12 so far, that,
together with BRCA1, are involved in homologous recombi-
nation DNA repair mechanisms [35, 85, 193]. Mutations in
FANCJ (=BRIP1) and FANCN (= PALB2) are associated with
a two fold increased risk of breast cancer [145, 158]. The
remaining ten FA genes may likewise be involved in the
carcinogenesis of breast cancer but their role has not been
elucidated yet. It has been suggested that the remaining FA
genes are inactivated through epigenetic/transcriptional mech-
anisms. For example, the FANCD2 protein is down regulated
in sporadic and in hereditary breast carcinomas [189].
1.4.9 Mismatch repair
Postreplication mismatch repair (MMR) is a critical
mechanism for maintaining microsatellite stability through
the correction of base substitution mismatches and inser-
tion/deletion events. The mismatch repair genes (MMR),
MLH1, MSH2 and MSH6, play a role in hereditary non-
polyposis colorectal cancer, the Lynch-syndrome. In a few
of these families, breast cancer is part of this syndrome,
which seems to be related to the absence of the MLH1and
MSH2 proteins [159]. Furthermore, a causative role of
MSH6 in the occurrence of breast cancer has been
suggested but only one case has been reported so far [70].
Together with BRCA1 and BRCA2, the above described
genes account for most, but not all, hereditary breast cancers
(Fig. 2). Obviously, the search for other genes involved in
hereditary breast cancer is still continuing [149].
1.5 Pathology of non-BRCA1 or non-BRCA2 related breast
cancers
Phenotypic characteristics of cancers developing in patients
with a strong family history without a BRCA1 or BRCA2
germlinemutation are various. These breast cancers develop as
a consequence of mutations in different moderate to low
penetrance genes, like the genes mentioned earlier (see









Fig. 2 Affected genes in hereditary breast cancer
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established that these tumors have even a lower grade
compared to sporadic breast cancers. Furthermore, the immu-
nophenotype is more or less the same as shown in sporadic
breast disease [76, 98]. One study describing a gene
expression profile of non-BRCA related breast cancer was
able to classify these tumors into two homogenous subsets,
ribosomal genes were more represented in one of these groups
compared to the other based on a 60 gene set. Additional
experiments should be done on these non-BRCA related
tumors to further describe their molecular characteristics [62].
1.5.1 CHEK2
Morphologic and immunophenotypic studies of breast
cancer in patients with a CHEK2 mutation has yielded
conflicting results, largely due to the limited cases of breast
cancers that have been found being related to this mutation.
Studies on ER and PR expression have reported contradic-
tory results, ranging from similar to overexpression of ER
and PR. Breast cancer in patients with a U157T mutation
has been associated with an increased incidence of lobular
carcinomas as has been described earlier [77, 81].
1.5.2 PALB2
A recent study describes for the first time some tumors
characteristics of PALB2, 1592delT, mutation carriers. Most
of these breast tumors exhibited a phenotype of high grade
mostly of ductal type and ER, PR and HER-2/neu receptor
negativity. They were mostly CK5/6, CK14 and CK17
negative, showed high expression of Ki67 and low
expression of Cyclin D1 as compared with other familial
and sporadic patients [67]
In conclusion, the pathology of hereditary breast cancers
not related to a BRCA1 or BRCA2 mutation has not been
studied extensively and so far does not seem very specific.
2 Clinical relevance
Surgical options for surveillance include prophylactic
bilateral mastectomy and prophylactic bilateral salpingo-
oophorectomy (BSO) [146]. Prophylactic bilateral mastec-
tomy reduces the risk of breast cancer by almost 100% in
mutation carriers [63, 116]. In view of the additional high
lifetime risk of ovarian cancer, especially in BRCA1
mutation carriers, these women are strongly advised to
undergo BSO including the removal of the Fallopian tubes
at the completion of childbearing [89, 105, 142].
Preliminary results from one study suggests that the use
of hormone therapy in postmenopausal women with a
BRCA1 mutation was associated with a decreased risk of
breast cancer. It is important to confirm this in a larger
study including different populations and a longer study
period [39].
The association of negativity ER/PR/HER-2/neu status
classifies many of BRCA1 related cancers in the “triple
negative” category, which is clinically under scrutiny as
these cancers may require an alternate chemotherapeutic
approach. Due to the important role of the BRCA genes in
DNA repair it could be expected that DNA cross linking
agents, like cisplatin and mitomycine-c, would have an effect
especially in those diseases that occur as a consequence of
mutated and therefore dysfunctional BRCA1 and BRCA2
genes [181]. Higher tumor responses to platinum based
chemotherapy have indeed been observed in patients with
BRCA1 mutated ovarian cancers when compared with the
effects observed in non hereditary ovarian cancer [26, 28].
A potentially new strategy that has emerged for
treatment of BRCA1 and BRCA2 related tumors is the use
of poly(ADP-ribose) polymerase 1 (PARP1) inhibitors.
BRCA1 and BRCA2 are both involved in DNA double
strand break repair, as mentioned before. PARP1 is
involved in base excision repair, a key pathway in the
repair of DNA single strand break. The absence of PARP
leads to spontaneous single strand breaks which collapse
replication forks into double strand breaks, triggering
homologous recombination for repair. However, with the
loss of functional BRCA1 or BRCA2, cells will be sensitized
to inhibit PARP activity, apparently leading to the persis-
tence of the DNA lesions which are usually repaired by
homologous recombination. When both pathways are
defect this will result in chromosomal instability, cell cycle
arrest and finally apoptosis. Cell survival assays show that
cell lines lacking wildtype BRCA1 or BRCA2 were
extremely sensitive to PARP inhibitors compared to
heterozygous mutant or the wildtype cells [43]. Similar
results were obtained using non embryonic cells deficient
for BRCA2. These results suggest the potential use of PARP
inhibitors in the treatment of BRCA1 and BRCA2 related
breast cancer. This is presently evaluated in various clinical
trials in BRCA carriers suffering from breast and/or ovarian
cancer [25, 43, 68, 180].
3 Conclusions
BRCA1 related breast cancers are very well characterized
by morphological, immunohistochemical and molecular
features that clearly help to differentiate them from sporadic
tumors and identify high risk patients for mutation testing.
BRCA2 related breast cancers on the other hand, offer yet
only a few morphological, immunohistochemical or molec-
ular features to separate them from sporadic controls.
Finally, although numbers studied so far are small, breast
cancers caused by other breast cancer susceptibility genes
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do not, as in BRCA2 related disease, seem to differ
significantly from sporadic breast cancers.
More studies should be performed on morphological,
immunohistochemical and molecular characterization of
BRCA2 related breast cancers, breast cancers caused by
unclassified variants of BRCA1 and BRCA2, and breast
cancers caused by other breast cancer susceptibility genes
to gain insight into the development of these breast cancers,
and to subsequently be able to offer clues for diagnosis and
new therapeutic approaches.
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